Non-endoscopic Brushing of the Esophagus Using a Non-endoscopic Inflatable Balloon of the Esophagus in Screening for Barrett Esophagus
NCT ID: NCT02451124
Last Updated: 2019-11-06
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
156 participants
INTERVENTIONAL
2015-07-31
2017-01-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
C2 CryoBalloon™ 180 Ablation System Dose De-escalation Study.
NCT03311451
Endoscopic Tri-Modal Imaging in Patients With Barrett's Esophagus
NCT00586989
Confocal Endomicroscopy for Barrett's Esophagus
NCT00487695
High Resolution Virtual Chromoendoscopy Versus Seattle Protocol for the Surveillance of Barrett's Esophagus
NCT05229783
Real-time Computer Aided Detection of Barrett's Neoplasia
NCT05628441
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To determine acceptability of non-endoscopic balloon brushing of esophagus.
II. To demonstrate successful performance of the methylation of vimentin (mVIM) assay in balloon brushings from subjects with and without Barrett's Esophagus (BE).
III. To examine molecular and histological factors that might lead to false negative and false positive mVIM assays in BE screening.
IV. To assay additional methylated deoxyribonucleic acid (DNA) biomarkers that might improve the sensitivity and specificity of mVIM in balloon brushings.
OUTLINE:
Patients undergo non-endoscopic brushing of the esophagus using a non-endoscopic inflatable balloon for the esophagus over 30-60 minutes followed by a standard esophagogastroduodenoscopy (EGD).
After completion of study, patients with serious adverse events are followed up until resolution, stabilization, or until it has been determined that the study treatment or participation is not the cause.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Screening: non-endoscopic inflatable balloon for the esophagus
Patients undergo non-endoscopic brushing of the esophagus using a non-endoscopic inflatable balloon for the esophagus over 30-60 minutes followed by a standard esophagogastroduodenoscopy. Questionnaire administration will provide self-reported data on patient experiences. laboratory biomarker analysis of biopsy will confirm diagnosis.
non-endoscopic inflatable balloon for the esophagus
Undergo non-endoscopic brushing of the esophagus using a non-endoscopic inflatable balloon for the esophagus
Questionnaire Administration
Ancillary studies
Laboratory Biomarker Analysis
Correlative studies
esophagogastroduodenoscopy
Standard of care, patients digestive tract scoped post balloon brushing
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
non-endoscopic inflatable balloon for the esophagus
Undergo non-endoscopic brushing of the esophagus using a non-endoscopic inflatable balloon for the esophagus
Questionnaire Administration
Ancillary studies
Laboratory Biomarker Analysis
Correlative studies
esophagogastroduodenoscopy
Standard of care, patients digestive tract scoped post balloon brushing
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients can provide informed consent
* Patients have no known coagulopathy and no known history of esophageal varices
Exclusion Criteria
* Patients have known coagulopathies or history of esophageal varices
* Patients do not have the ability to give informed consent
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Case Comprehensive Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Amitabh Chak
Role: PRINCIPAL_INVESTIGATOR
Case Comprehensive Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Informed Consent Form
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2015-00246
Identifier Type: REGISTRY
Identifier Source: secondary_id
CASE6214
Identifier Type: OTHER
Identifier Source: secondary_id
CASE6214
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.